<description>&lt;p&gt;&lt;em&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; Neurology Today&lt;/span&gt;&lt;/em&gt; &lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses the Medicare’s proposed coverage of carotid stenting in asymptomatic patients,neuro-oncologists’ perspectives on a federal initiative to target persistent poverty in vulnerable patients, and the technological promise of a new optical EMG for neuromuscular disorders.&lt;/span&gt;&lt;/p&gt;</description>

Neurology Today in 5

American Academy of Neurology

Medicare coverage of carotid stenting, disparities in vulnerable neuro-oncology patients, optical EMG for neuromuscular disorders.

SEP 21, 20235 MIN
Neurology Today in 5

Medicare coverage of carotid stenting, disparities in vulnerable neuro-oncology patients, optical EMG for neuromuscular disorders.

SEP 21, 20235 MIN

Description

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses the Medicare’s proposed coverage of carotid stenting in asymptomatic patients,neuro-oncologists’ perspectives on a federal initiative to target persistent poverty in vulnerable patients, and the technological promise of a new optical EMG for neuromuscular disorders.